Table 1.
Types of Malignancies by Treatment Group—Strategic Timing of Antiretroviral Treatment (START) Trial
| Malignancy | Immediate cART | Deferred cART |
|---|---|---|
| Infection-related cancer | ||
| Human herpesvirus 8: Kaposi sarcoma | 1 | 11 |
| Epstein-Barr virus | ||
| Non-Hodgkin lymphoma | 2 | 9 |
| Hodgkin lymphoma | 1 | 1 |
| Human papillomavirus | ||
| Anal cancer | 1 | 2 |
| Cervical cancer | 1 | 0 |
| Total | 6 | 23 |
| Infection-unrelated cancer | ||
| Prostate | 2 | 3 |
| Lung | 2 | 2 |
| Testicular | 0 | 2 |
| Multiple myeloma | 1 | 0 |
| Fibrosarcoma | 1 | 0 |
| Breast | 0 | 1 |
| Bladder | 1 | 0 |
| Ureteral | 0 | 1 |
| Malignant melanoma | 0 | 1 |
| Myeloid leukemia | 0 | 1 |
| Thyroid | 0 | 1 |
| Leiomyosarcoma | 0 | 1 |
| Squamous cell carcinoma of the skin | 1 | 0 |
| Squamous cell carcinoma of the head/neck | 0 | 1 |
| Gastric adenocarcinoma | 0 | 1 |
| Liver | 0 | 1 |
| Total | 8 | 16 |
Abbreviation: cART, combination antiretroviral therapy.